Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RNAZ 
Transcode Therapeutics Inc (RNAZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: RNAZ (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -91.33% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.38M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 1.48 | 52 Weeks Range 6.15 - 739.20 | Updated Date 08/29/2025 |
52 Weeks Range 6.15 - 739.20 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -61.43 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -1.64 | Actual -5.13 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -139.89% | Return on Equity (TTM) -658.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2464015 | Price to Sales(TTM) - |
Enterprise Value 2464015 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.59 | Shares Outstanding 833683 | Shares Floating 832424 |
Shares Outstanding 833683 | Shares Floating 832424 | ||
Percent Insiders 0.15 | Percent Institutions 4.43 |
Upturn AI SWOT
Transcode Therapeutics Inc
Company Overview
History and Background
Transcode Therapeutics Inc., founded in 2010, is a clinical-stage biopharmaceutical company focused on developing RNA therapeutics for the treatment of cancer. They are pioneering a new class of drugs designed to selectively block or enhance gene expression using RNA.
Core Business Areas
- Therapeutic Development: Developing and commercializing RNA-based therapeutics for cancer treatment.
- TTX Platform: Utilizing their proprietary TTX delivery platform to deliver RNA molecules directly to cancer cells.
Leadership and Structure
The leadership team consists of individuals with experience in drug development and the biopharmaceutical industry. The organizational structure includes research and development, clinical operations, and management teams.
Top Products and Market Share
Key Offerings
- TTX-MC138: The company's lead product candidate, TTX-MC138, is being developed for the treatment of recurrent or metastatic cancers. Currently in clinical trials. Market share is not yet applicable as it is pre-commercialization. Competitors include companies developing similar RNA-based therapeutics and standard chemotherapy treatments.
Market Dynamics
Industry Overview
The RNA therapeutics market is rapidly growing, driven by advancements in RNA delivery technologies and the potential for targeted therapies. The oncology market specifically is vast with significant unmet needs.
Positioning
Transcode Therapeutics is positioned as a player in the RNA therapeutics space, focusing on innovative delivery methods for targeted cancer treatment. Their competitive advantage lies in their TTX platform, which may offer improved delivery efficiency.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Transcode Therapeutics aims to capture a portion of this TAM through its targeted RNA therapeutics. TAM is large and it is working to secure a portion of the market through their products.
Upturn SWOT Analysis
Strengths
- Proprietary TTX delivery platform
- Focus on RNA therapeutics
- Clinical-stage development
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on single lead product candidate
- High risk of clinical trial failure
- Limited commercial infrastructure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new RNA therapeutics
- Positive clinical trial results
- Advancements in RNA delivery technologies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Patent challenges
Competitors and Market Share
Key Competitors
- MRNA
- ALNY
- IONS
Competitive Landscape
Transcode faces competition from larger, more established companies with greater financial resources and broader pipelines. Its TTX platform offers a potential competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Growth has been focused on research and development, advancing TTX-MC138 through clinical trials.
Future Projections: Future growth depends on the successful completion of clinical trials and potential commercialization of TTX-MC138 or other pipeline products.
Recent Initiatives: Recent initiatives include ongoing clinical trials for TTX-MC138 and exploration of new RNA therapeutic targets.
Summary
Transcode Therapeutics is a clinical-stage biopharmaceutical company with a focus on RNA therapeutics and a proprietary delivery platform. The company's success hinges on the clinical progress and potential commercialization of TTX-MC138. It faces challenges due to limited financial resources and competition but also has opportunities through partnerships and pipeline expansion. Investors should closely monitor clinical trial results and the company's cash position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Market reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Transcode Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-07-08 | Interim CEO, CFO, President, VP of Administration & Director Mr. Thomas A. Fitzgerald M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | |
Full time employees 7 | |||
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.